Latest Insider Transactions at Hookipa Pharma Inc. (HOOK)
This section provides a real-time view of insider transactions for Hookipa Pharma Inc. (HOOK). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of HOOKIPA Pharma Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of HOOKIPA Pharma Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 22
2024
|
Malte Peters Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
108,695
+50.0%
|
-
|
|
Jul 22
2024
|
Mary Theresa Coelho EVP and CFO |
BUY
Grant, award, or other acquisition
|
Direct |
69,875
+50.0%
|
-
|
|
Aug 21
2023
|
Reinhard Kandera Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
7,000
+13.97%
|
$0
$0.72 P/Share
|
|
Aug 16
2023
|
Reinhard Kandera Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
8,000
+18.14%
|
$0
$0.71 P/Share
|
|
Jul 11
2023
|
Jorn Aldag Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+6.5%
|
$0
$0.83 P/Share
|
|
Jul 07
2023
|
Jorn Aldag Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+6.95%
|
$0
$0.81 P/Share
|
|
Jul 05
2023
|
Jorn Aldag Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+7.47%
|
$0
$0.89 P/Share
|
|
Jul 03
2023
|
Jorn Aldag Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+8.07%
|
$0
$0.89 P/Share
|
|
Jun 30
2023
|
Reinhard Kandera Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
12,000
+29.93%
|
$0
$0.88 P/Share
|
|
Feb 01
2022
|
Jorn Aldag Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
47,824
+47.93%
|
$143,472
$3.0 P/Share
|
|
Feb 01
2022
|
Reinhard Kandera Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
14,056
+46.62%
|
$42,168
$3.0 P/Share
|
|
Feb 01
2022
|
Igor Matushansky Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
14,933
+12.97%
|
$44,799
$3.0 P/Share
|
|
Feb 01
2022
|
Roman Necina Chief Operations Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,892
+46.43%
|
$38,676
$3.0 P/Share
|
|
Feb 01
2022
|
Christine D. Baker Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,658
+45.81%
|
$40,974
$3.0 P/Share
|
|
Feb 01
2022
|
Klaus Orlinger Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,188
+46.9%
|
$27,564
$3.0 P/Share
|
|
Dec 21
2021
|
Igor Matushansky Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
14,949
-5.62%
|
$29,898
$2.49 P/Share
|
|
Dec 21
2021
|
Igor Matushansky Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
22,853
+7.81%
|
$0
$0.1 P/Share
|
|
Apr 21
2021
|
Capital Vi Fcpr Sofinnova > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
328,620
-9.37%
|
$3,614,820
$11.6 P/Share
|
|
Mar 29
2021
|
Capital Vi Fcpr Sofinnova > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
36,829
-1.04%
|
$478,777
$13.67 P/Share
|
|
Mar 26
2021
|
Capital Vi Fcpr Sofinnova > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
35,171
-0.98%
|
$457,223
$13.69 P/Share
|
|
Mar 25
2021
|
Capital Vi Fcpr Sofinnova > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
28,546
-0.79%
|
$371,098
$13.12 P/Share
|
|
Mar 24
2021
|
Capital Vi Fcpr Sofinnova > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
52,690
-1.44%
|
$684,970
$13.7 P/Share
|
|
Mar 23
2021
|
Capital Vi Fcpr Sofinnova > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
40,000
-1.08%
|
$520,000
$13.91 P/Share
|
|
Mar 22
2021
|
Capital Vi Fcpr Sofinnova > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
40,534
-1.08%
|
$567,476
$14.54 P/Share
|
|
Mar 19
2021
|
Capital Vi Fcpr Sofinnova > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
166,230
-4.26%
|
$2,327,220
$14.6 P/Share
|
|
Dec 17
2020
|
Igor Matushansky Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
27,979
-16.37%
|
$307,769
$11.73 P/Share
|
|
Dec 17
2020
|
Igor Matushansky Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
48,988
+22.17%
|
$0
$0.1 P/Share
|
|
Dec 16
2020
|
Igor Matushansky Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
380
-0.67%
|
$4,180
$11.7 P/Share
|
|
Dec 16
2020
|
Igor Matushansky Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
640
+1.11%
|
$0
$0.1 P/Share
|
|
Oct 21
2020
|
Jan Van De Winkel |
BUY
Grant, award, or other acquisition
|
Direct |
9,153
+50.0%
|
-
|
|
Oct 21
2020
|
Michael Aaron Kelly Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,754
+50.0%
|
-
|
|
Oct 21
2020
|
David Ross Kaufman |
BUY
Grant, award, or other acquisition
|
Direct |
4,577
+50.0%
|
-
|
|
Oct 21
2020
|
Christoph Lengauer Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,603
+50.0%
|
-
|
|
Oct 21
2020
|
Julie O'Neill |
BUY
Grant, award, or other acquisition
|
Direct |
4,969
+50.0%
|
-
|
|
Oct 21
2020
|
Sander Van Deventer Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,485
+50.0%
|
-
|
|
Oct 21
2020
|
Graziano Seghezzi Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,708
+50.0%
|
-
|
|
Oct 02
2020
|
Capital Vi Fcpr Sofinnova > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
300
-0.01%
|
$3,000
$10.0 P/Share
|
|
Apr 23
2019
|
Redmile Group, LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
999,322
+50.0%
|
-
|
|
Apr 23
2019
|
Baker Bros. Advisors LP |
BUY
Open market or private purchase
|
Indirect |
892,857
+50.0%
|
$12,499,998
$14.0 P/Share
|